265 related articles for article (PubMed ID: 33459338)
1. A pipeline to evaluate inhibitors of the Pseudomonas aeruginosa exotoxin U.
Foulkes DM; McLean K; Zheng Y; Sarsby J; Haneef AS; Fernig DG; Winstanley C; Berry N; Kaye SB
Biochem J; 2021 Feb; 478(3):647-668. PubMed ID: 33459338
[TBL] [Abstract][Full Text] [Related]
2. Impact of fluoroquinolones and aminoglycosides on P. aeruginosa virulence factor production and cytotoxicity.
Foulkes DM; McLean K; Sloniecka M; Rustidge S; Byrne DP; Haneef AS; Winstanley C; Berry N; Fernig DG; Kaye SB
Biochem J; 2022 Dec; 479(24):2511-2527. PubMed ID: 36504127
[TBL] [Abstract][Full Text] [Related]
3. Traversal of multilayered corneal epithelia by cytotoxic Pseudomonas aeruginosa requires the phospholipase domain of exoU.
Ramirez JC; Fleiszig SM; Sullivan AB; Tam C; Borazjani R; Evans DJ
Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):448-53. PubMed ID: 22167094
[TBL] [Abstract][Full Text] [Related]
4. Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU.
Lee VT; Pukatzki S; Sato H; Kikawada E; Kazimirova AA; Huang J; Li X; Arm JP; Frank DW; Lory S
Infect Immun; 2007 Mar; 75(3):1089-98. PubMed ID: 17178785
[TBL] [Abstract][Full Text] [Related]
5. Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review.
Sawa T; Shimizu M; Moriyama K; Wiener-Kronish JP
Crit Care; 2014 Dec; 18(6):668. PubMed ID: 25672496
[TBL] [Abstract][Full Text] [Related]
6. Development, Optimization, and Validation of a High Throughput Screening Assay for Identification of Tat and Type II Secretion Inhibitors of
Massai F; Saleeb M; Doruk T; Elofsson M; Forsberg Å
Front Cell Infect Microbiol; 2019; 9():250. PubMed ID: 31355152
[TBL] [Abstract][Full Text] [Related]
7. Molecular Detection of the Virulent ExoU Genotype of Pseudomonas aeruginosa Isolated from Infected Surgical Incisions.
Hassuna NA
Surg Infect (Larchmt); 2016 Oct; 17(5):610-4. PubMed ID: 27441791
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread.
Allewelt M; Coleman FT; Grout M; Priebe GP; Pier GB
Infect Immun; 2000 Jul; 68(7):3998-4004. PubMed ID: 10858214
[TBL] [Abstract][Full Text] [Related]
9. In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors.
Phillips RM; Six DA; Dennis EA; Ghosh P
J Biol Chem; 2003 Oct; 278(42):41326-32. PubMed ID: 12915403
[TBL] [Abstract][Full Text] [Related]
10. Comparison of virulence factors in Pseudomonas aeruginosa strains isolated from contact lens- and non-contact lens-related keratitis.
Choy MH; Stapleton F; Willcox MDP; Zhu H
J Med Microbiol; 2008 Dec; 57(Pt 12):1539-1546. PubMed ID: 19018027
[TBL] [Abstract][Full Text] [Related]
11. Interactions of the effector ExoU from
Springer TI; Reid TE; Gies SL; Feix JB
J Biol Chem; 2019 Dec; 294(50):19012-19021. PubMed ID: 31662432
[No Abstract] [Full Text] [Related]
12. Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia.
Howell HA; Logan LK; Hauser AR
mBio; 2013 Mar; 4(2):e00032-13. PubMed ID: 23481600
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of biofilm production and characterization of genes encoding type III secretion system among Pseudomonas aeruginosa isolated from burn patients.
Jabalameli F; Mirsalehian A; Khoramian B; Aligholi M; Khoramrooz SS; Asadollahi P; Taherikalani M; Emaneini M
Burns; 2012 Dec; 38(8):1192-7. PubMed ID: 22995427
[TBL] [Abstract][Full Text] [Related]
14. Difference of Type 3 secretion system (T3SS) effector gene genotypes (exoU and exoS) and its implication to antibiotics resistances in isolates of Pseudomonas aeruginosa from chronic otitis media.
Park MH; Kim SY; Roh EY; Lee HS
Auris Nasus Larynx; 2017 Jun; 44(3):258-265. PubMed ID: 27461174
[TBL] [Abstract][Full Text] [Related]
15. Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU.
Pankhaniya RR; Tamura M; Allmond LR; Moriyama K; Ajayi T; Wiener-Kronish JP; Sawa T
Crit Care Med; 2004 Nov; 32(11):2293-9. PubMed ID: 15640644
[TBL] [Abstract][Full Text] [Related]
16. Implications of oxidative stress in the cytotoxicity of Pseudomonas aeruginosa ExoU.
Saliba AM; de Assis MC; Nishi R; Raymond B; Marques Ede A; Lopes UG; Touqui L; Plotkowski MC
Microbes Infect; 2006 Feb; 8(2):450-9. PubMed ID: 16293434
[TBL] [Abstract][Full Text] [Related]
17. Molecular detection of type III secretory toxins in Pseudomonas aeruginosa isolates.
Jarjees KK
Cell Mol Biol (Noisy-le-grand); 2020 Jul; 66(5):9-14. PubMed ID: 33040805
[TBL] [Abstract][Full Text] [Related]
18. ExoU Induces Lung Endothelial Cell Damage and Activates Pro-Inflammatory Caspase-1 during
Hardy KS; Tuckey AN; Renema P; Patel M; Al-Mehdi AB; Spadafora D; Schlumpf CA; Barrington RA; Alexeyev MF; Stevens T; Pittet JF; Wagener BM; Simmons JD; Alvarez DF; Audia JP
Toxins (Basel); 2022 Feb; 14(2):. PubMed ID: 35202178
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 4,5-Bisphosphate-Dependent Oligomerization of the Pseudomonas aeruginosa Cytotoxin ExoU.
Zhang A; Veesenmeyer JL; Hauser AR
Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993456
[TBL] [Abstract][Full Text] [Related]
20.
Foulkes DM; McLean K; Haneef AS; Fernig DG; Winstanley C; Berry N; Kaye SB
Microorganisms; 2019 Dec; 7(12):. PubMed ID: 31888268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
